KR101502514B1 - Compositions for improving blood circulation and blood-lipids - Google Patents

Abstract

The present invention relates to a composition for improving blood circulation comprising 75-98% by weight of vegetable omega 3, 0.001-10% by weight of the whole composition of Ginkgo biloba extract and 0.001-15% by weight of vegetable vitamin . The omega-3 contained in the composition of the present invention is vegetable omega-3 extracted from microalgae and is excellent in blood circulation improvement and cholesterol lowering effect. In addition, a composition further comprising a ginseng lipid-soluble component in a composition of vegetable omega-3, ginkgo leaf extract, and vegetable vitamin has better cholesterol and neutral lipid lowering efficacy. When the composition of the present invention is ingested, the amount of triglyceride and LDL-cholesterol is reduced and the blood circulation improving effect is further enhanced. Therefore, the composition can be used as a pharmaceutical composition for improving blood circulation or a health food composition.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for improving blood circulation or blood lipids,

The present invention relates to a composition for improving blood circulation or improving blood lipids.

The health of modern people is threatened by various adult diseases due to changes in eating habits and life patterns. One of the representative adult diseases is arteriosclerosis, a cardiovascular disease, and its incidence is increasing. Therefore, there are many studies on foods and medicines that can effectively control the blood cholesterol and triglyceride concentration, which are important for the treatment and prevention of cardiovascular diseases. The development of natural medicinal materials has great significance in the economic and industrial fields. Especially, development of natural medicinal materials which are effective for improving blood circulation and lowering cholesterol while having no adverse effects on the human body is desperately required.

Cholesterol levels are a major precursor of cardiovascular diseases, such as arterial occlusive disease, varicose veins, venous thrombosis, Burger's disease, lymphadenopathy, peripheral vascular disease, hypertension, hyperlipidemia, angina pectoris or stroke, The cholesterol found in the lipids of the bloodstream is used to produce cell membranes, some hormones and tissues. High levels of cholesterol in the blood (hypercholesterolemia) are the major risk factors for coronary heart disease, resulting in heart failure.

Omega-3 fatty acid oils are useful for the treatment of autoimmune and inflammatory diseases such as inflammatory bowel diseases such as rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis; Immunosuppressive therapy; Prevention of hypertension in normal human and heart transplant patients; Coronary heart disease; Hyperlipidemia; And triglycerides; Have the property that they can be used for numerous therapeutic advantages including improved kidney function and improved nephrotoxicity reduction. The use of omega-3 fatty acid oil is disclosed in U.S. Patent No. 5,034,415 (diabetes), U.S. Patent No. 4,843,095 (rheumatoid arthritis), Japanese Patent No. 2253629 (anticancer), U.S. Patent No. 4,879,312 1290625 (Enhancement of cerebral function), U.S. Patent No. 5,457,130 (Malignant tumor, inhibition of lipolytic activity) and U.S. Patent No. 5,436,269 (Hepatitis).

The omega-3 can be classified into animal omega-3 extracted from fish and vegetable omega-3 extracted from algae, perilla, flaxseed and the like. In the present invention, blood circulation using vegetable omega-3, ginkgo biloba extract and plant- And a cholesterol-lowering food composition.

Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.

The present inventors have made extensive efforts to develop a food composition having improved blood circulation and cholesterol-lowering effects. As a result, it was confirmed that the composition containing the vegetable omega-3 was excellent in blood circulation improvement and cholesterol-lowering effect, and in particular, the composition containing vegetable omega 3, ginkgo leaf extract and plant vitamin .

It is therefore an object of the present invention to provide a food composition for improving blood circulation or improving blood lipids.

It is another object of the present invention to provide a food composition for obesity control.

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.

According to one aspect of the present invention, the present invention provides a composition comprising 75-99% by weight of vegetable omega 3, 0.001-10% by weight of the ginkgo leaf extract, and 0.001-15% by weight of vegetable vitamin And a food composition for improving blood circulation or improving blood lipids.

The present inventors have made extensive efforts to develop a food composition having improved blood circulation and cholesterol-lowering effects. As a result, it was confirmed that the composition containing the vegetable omega-3 was excellent in blood circulation improvement and cholesterol-lowering effect, and in particular, the composition containing vegetable omega 3, ginkgo leaf extract and plant vitamin .

The vegetable omega-3s used in the food composition of the present invention may be derived from large algae, microalgae, and plants, for example, purple laver, dulse and poultry (Ulva lactuca) , Large algae such as kelp; Microalgae such as Spirulina, Chlorella, and Schizochytrium ; And plants such as flaxseed or perilla. In particular, the microalgae of Schizochytrium sp. Contain a large amount of docosahexaenoic acid (DHA) and are used as raw materials for biomass or biofuels.

According to a preferred embodiment of the present invention, the vegetable omega-3 used in the food composition of the present invention is derived from microalgae, more preferably from one or more microorganisms selected from the group consisting of spirulina, chlorella, And more preferably from Schizochytrium aggregatum or from Schizochytrium minutum , and more preferably from Schizochytrium < RTI ID = 0.0 > minutum . ≪ / RTI >

The vegetable omega-3 contained in the food composition of the present invention is an essential unsaturated fatty acid, which is not synthesized in the human body but is essential for metabolism. Omega-3 fatty acids important for nutrition include alpha-linolenic acid (ALA) (EPA) and docosahexaenoic acid (DHA). The vegetable omega-3s include various omega-3 fatty acid components known in the art and include, for example, alpha-linolenic acid, hexadecatrienoic acid, octadecatrienoic acid, octadecatetraenoic acid, eicosatrienoic acid, Alpha-linolenic acid (ALA), tetracosapentaenoic acid, tetracosapentaenoic acid, and tetracosapentaenoic acid, preferably alpha-linolenic acid (ALA), eicosapentaenoic acid, heneicosapentaenoic acid, docosapentanoic acid, docosahexaenoic acid, , Eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA).

The ginkgo leaf extract used in the food composition of the present invention can be obtained by various known extraction methods such as hot water extraction, organic solvent extraction, supercritical extraction, and the like, and further processes such as vacuum distillation and freeze drying or spray drying By weight.

The vegetable vitamins used in the food composition of the present invention are vitamins extracted from fruits, vegetables or algae, such as vitamin A1 (retinol), vitamin A2 (dihydrouretinol), vitamin D2 (ergocalciferol) and vitamin E Tocopherol); And Vitamin B12 (cyanocobalamin), vitamin C (ascorbic acid), vitamin C (ascorbic acid), vitamin C (ascorbic acid) and vitamin B (thiamine), vitamin B2 (riboflavin), vitamin B3 And water-soluble vitamins of folic acid. Preferably, the vegetable vitamin includes niacin, pantothenic acid, vitamin B6 hydrochloride, vitamin B2, vitamin B1 hydrochloride, folic acid or biotin.

The food composition of the present invention comprises 75-99% by weight of vegetable omega 3, 0.001-10% by weight of the ginkgo leaf extract, and 0.001-15% by weight of vegetable vitamin to the total composition, based on the total composition; Preferably from 85 to 98% by weight of vegetable omega 3, 0.5 to 5% by weight of the ginkgo leaf extract, based on the total composition, and 0.5 to 10% by weight of the plant vitamin, based on the total composition; Even more preferably, the composition comprises 92-98% by weight vegetable omega 3, 0.5-3% by weight of the ginkgo leaf extract for the total composition, and 0.5-5% by weight vegetable vitamin for the total composition ; Still more preferably 95-98 wt.% Vegetable omega 3, 0.5-2 wt.% Ginkgo leaf extract for the total composition, and 0.5-3 wt.% Vegetable vitamin for the total composition.

According to a preferred embodiment of the present invention, the food composition for improving blood circulation or lipid of the present invention may further comprise a blood circulation improving agent in addition to the vegetable omega-3, ginkgo leaf extract and vegetable vitamin. Preferably, the blood circulation improving agent is omega-6 fatty acid, omega-7 fatty acid, omega-9 fatty acid or lecithin, and the omega-6 fatty acid is, for example, octadecadienoic acid, octadecatrienoic acid, Eicosatetraenoic acid, docosadienoic acid, docosatetraenoic acid, docosapentaenoic acid, tetracosatetraenoic acid, tetracosapentaenoic acid, and octadecatrienoic acid are preferable. 7 fatty acids include, for example, dodecenoic acid, tetradecenoic acid, hexadecenoic acid, decenoic acid, eicosanoic acid, docosanoic acid and tetracosenoic acid, and the omega-9 fatty acids include, for example, , Octadecenoic acid, eicosanoic acid, eicosatrienoic acid, docosanoic acid and tetracosenoic acid.

Meanwhile, the food composition for improving blood circulation or blood lipid of the present invention may further comprise a ginseng lipid-soluble component in addition to the vegetable omega-3, ginkgo leaf extract and vegetable vitamin. Preferably, the ginseng lipid-soluble component may further comprise 0.05-3 parts by weight, more preferably 0.1-3 parts by weight, of the ginseng lipid-soluble component per 100 parts by weight of the composition for improving blood circulation or blood lipid composition, More preferably from 0.1 to 2.5 parts by weight based on the total composition, even more preferably from 0.3 to 2 parts by weight based on the total composition.

The ginseng lipid soluble component contained in the composition of the present invention may be derived from various ginsengs such as white ginseng, ginseng, black ginseng, ginseng, raw ginseng, Taegeuk ginseng, wild ginseng, camellia ginseng or goat ginseng, . Ginseng used in the present invention can be employed a known variety of ginseng, goryeosam (Panax ginseng , P. quiquefolius , P. notoginseng , P. japonicus , P. trifolium , P. pseudoginseng , and P. vietnamensis . But are not limited thereto.

The ginseng lipid-soluble ingredient used in the present invention can be obtained by various known extraction methods such as hot water extraction, organic solvent extraction, supercritical extraction, and the like, and further processed such as by vacuum distillation, freeze drying, spray drying, . ≪ / RTI >

According to one embodiment of the present invention, the ginseng lipid soluble component can be obtained by using a supercritical extraction method.

Extracts containing ginseng fat-soluble ingredients include those obtained using supercritical fluids, as well as those obtained by further application of the purification process. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained through the purification method is also included in the ginseng lipid-soluble component extract of the present invention.

The supercritical extraction method of the ginseng lipid soluble component contained in the composition of the present invention will be described in detail in each step as follows:

Step (a): Step of putting ginseng in supercritical extraction vessel

The manufacturing method of the present invention includes a step of processing ginseng into a suitable form and putting it into a supercritical extraction container.

The ginseng used in the present invention can be cultivated or marketed, and can be used in a dried, frozen state, or natural raw materials.

According to the method of the present invention, the ginseng is pulverized or cut to an appropriate size in order to maximize the contact area with the solvent.

Step (b): Extraction of fat-soluble components of ginseng

Next, supercritical fluid is applied to the supercritical extraction vessel of step (a) to extract ginseng lipid soluble components.

As used herein, the term " supercritical fluid " refers to a fluid that is above the critical temperature and pressure, and has unique properties that distinguish it from conventional solvent extraction methods. When a material in a supercritical state changes its pressure near its critical point, many physical properties such as density, viscosity, diffusion coefficient, and polarity continuously change greatly from gas close to liquid state. When the liquid carbon dioxide is put into a closed container and heated, the boundary of the gas - liquid gradually disappears as temperature and pressure increase. Supercritical fluid is a heavy fluid that fills an enclosed space like a gas. Supercritical fluid technology is a technique that exploits the advantages of supercritical fluids, such as high solubility, rapid mass transfer and heat transfer, low viscosity, high diffusion coefficient, and fast penetration into micropores due to low surface tension. The supercritical fluid diffuses into the medium faster than the liquid solvent and can extract the constituents from the medium with the solvent strength of the liquid still present. Fluids in the supercritical region can be freely controlled in a wide range of gas-to-liquid physical and chemical properties (density, diffusion coefficient, thermal conductivity, partial molar volume, solubility, hydrogen bond strength, etc.) And has a stronger point than general solvent extraction with temperature only parameters.

The supercritical fluid is carbon dioxide, ammonia, nitrogen, oxygen, helium, SO _2, ethane, ethylene, propane, propylene, sulfur hexafluoride, knitted Russ oxide, chloro trifluoromethanesulfonyl, monofluorophosphate methane to be used in the extraction process , Xenon, or a combination thereof, preferably the supercritical fluid is carbon dioxide.

Because carbon dioxide is the main component of the atmosphere, it can be obtained safely and easily. In addition, carbon dioxide can be purchased at relatively low cost. Since the amount of carbon dioxide used in the present invention does not adversely affect the atmosphere, compared to other supercritical fluids, carbon dioxide is environmentally friendly. In addition, oxygen dioxide is non-flammable and non-explosive and has the advantage of not leaving substantially any residue after evaporation. On the other hand, since the polarity of carbon dioxide changes depending on the temperature and the pressure, it can be adjusted to have polarity and non-polarity characteristics by controlling temperature and pressure as needed. By changing the temperature and pressure, the solvent properties of the carbon dioxide fluid can be changed, which allows the separation of various components into a single solvent system.

The extraction method of the present invention is preferably a supercritical extraction of ginseng at a temperature of 30-70 ° C and a pressure of 100-400 bar and a flow rate of supercritical fluid of 1-20 ml / min, more preferably at a temperature of 35- 65 ° C and pressure of 220-380 bar, and supercritical fluid flow rate of 10-20 ml / min. The ginseng lipid soluble components extracted under these conditions are characterized by excellent blood circulation improving effect.

One of the greatest features of the present invention is to provide an optimal supercritical extraction condition depending on the use site of the ginseng raw material. Accordingly, the supercritical extraction conditions are selected according to the use region of the ginseng raw material in the temperature and pressure ranges described above, thereby exhibiting excellent extraction yield. When the use area of the ginseng raw material is root of ginseng, the supercritical extraction condition of the ginseng is preferably 35-65 ° C, more preferably 35-55 ° C, even more preferably 35-45 ° C ego; The pressure is preferably 200-400 bar, more preferably 250-400 bar, even more preferably 300-400 bar, even more preferably 320-380 bar. According to one embodiment of the present invention, the supernatant extraction conditions of the ginseng lipid-soluble component of the ginseng root are 40 ° C. and 350 bar.

When the use area of the ginseng raw material is a ginseng body, the supercritical extraction condition of the ginseng is preferably 40-65 ° C, more preferably 50-65 ° C, even more preferably 55-65 ° C ego; The pressure is preferably 150-350 bar, more preferably 150-300 bar, even more preferably 200-300 bar, even more preferably 220-280 bar. According to one embodiment of the present invention, the supernatant extraction conditions of the ginseng lipid-soluble component of the ginseng body are a temperature of 60 ° C and a pressure of 250 bar.

On the other hand, the supercritical fluid extraction step is preferably performed at a flow rate of supercritical fluid of 1-20 ml / min, more preferably 10-20 ml / min, even more preferably 13-18 ml / min .

The ginseng lipid soluble component may be extracted and then subjected to additional filtration to remove impurities contained in the extract before application of step (c). A centrifuge, a pressure filter or a diatomaceous earth filter may be used as the filter.

The extraction method of the present invention may further use an auxiliary solvent to further improve the extraction yield of the ginseng lipid soluble component. For example, supercritical fluids and nonpolar solvents or supercritical fluids and polar solvents can be used. The nonpolar solvent includes any nonpolar solvent conventionally used in the art and is preferably selected from the group consisting of hexane, acetone, toluene, chloroform, dimethylsulfoxide (DMSO), tetrahydrofuran (THF), N, Dioxane, diethyl ether, N-methylpyrrolidone, benzene or mixtures thereof, preferably hexane. The polar solvent includes any polar solvent conventionally used in the art, and is preferably an alcohol, water, ethylene glycol, polyethylene glycol, propylene carbonate, formic acid, acetic acid, acetonitrile, chlorodifluoromethane Or a mixture thereof, more preferably an alcohol selected from the group consisting of methanol, ethanol, propanol, 1-hexanol, 2-methoxyethanol and combinations thereof, more preferably methanol or ethanol And even more preferably ethanol. If a co-solvent is used, the flow rate may be 1-10 ml / min, preferably 1-5 ml / min, and more preferably 1-3 ml / min.

Step (c): Obtaining ginseng fat-soluble component

A ginseng lipid soluble component is obtained from the extraction result of step (b).

The ginseng lipid soluble component extract of step (c) may be concentrated to a water content of 20% to 50%, and the concentrate may be prepared as a lyophilized powder. The concentration may be carried out by various methods known in the art, for example, by concentration under reduced pressure. The concentrate and the lyophilized powder may be used in the final product production through an ultra-high pressure sterilization process.

As used herein, the term " lipophilic component " includes organisms such as carbohydrates, proteins and the like that constitute the living body and include lipids (e.g. fatty acids, essential oils, plant sterols and organic acids) and phenolic compounds (polyacetylenes and terpenoids) .

As used herein, the term " fatty acid " refers to a carboxylic acid containing a long aliphatic chain, which includes both saturated and unsaturated fatty acids. The saturated fatty acid means a fatty acid which does not contain a carbon-carbon double bond and refers to a fatty acid having a general formula of CH ₃ (CH ₂ ) _n COOH (n is 1 to 34), and the unsaturated fatty acid has 1 or more Examples of the fatty acid containing a carbon-carbon double bond and a carboxyl group include n3 unsaturated fatty acid, n6 unsaturated fatty acid, n7 unsaturated fatty acid, n9 unsaturated fatty acid, and other 2-pyridinopropanoic acid, 3-nonenoic acid, cyclopropylmethylphosphinic acid, Cyclopropanecanoic acid.

According to a preferred embodiment of the present invention, the fat-soluble component is saturated fatty acid, n3 unsaturated fatty acid, n6 unsaturated fatty acid, n7 unsaturated fatty acid or n9 unsaturated fatty acid.

The n3 unsaturated fatty acid may be at least one selected from the group consisting of hexadecatrienoic acid, octadecatrienoic acid, octadecatetraenoic acid, eicosatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, heneicosapentaenoic acid, Tetradecosapentaenoic acid, tetracosapentaenoic acid and tetracohexaenoic acid, and the n6 unsaturated fatty acid is selected from the group consisting of octadecadienoic acid, octadecatrienoic acid, eicosadienoic acid, eicosatri Wherein the nano-unsaturated fatty acid is selected from the group consisting of nano-acid, eicosatetraenoic acid, docosadienoic acid, docosatetraenoic acid, docosapentaenoic acid, tetracosatetraenoic acid, tetracosapentaenoic acid and octadecatrienoic acid, Dodecanoic acid, decodecanoic acid, hexadecenoic acid, decenoic acid, eicosanoic acid, docosanoic acid, and tetracosenoic acid, and the n9 unsaturated fatty acid includes octadecenoic acid, And the acid, eicosyl four tree including acids, acid and tetra Toko three kose acid.

More preferably, the saturated fatty acid is selected from the group consisting of docosanoic acid, eicosanoic acid, heneicosanoic acid, dodecanoic acid, heptadecanoic acid, hexadecanoic acid, octadecanoic acid, octanoic acid, pentadecanoic acid, Succinic acid, nonadecanoic acid, hexanoic acid, decanoic acid, propanoic acid, undecanoic acid and 11,14-eicosanoic acid, and the unsaturated fatty acids are 11-eicosanoic acid, 11,13-eicosanoic acid, Hexadecenoic acid, 9-octadecenoic acid, 11-octadecenoic acid, 8,11-octadecadienoic acid, 9,12-octadecadienoic acid, Octadecadienoic acid, 9,15-octadecadienoic acid, eicosanoic acid, 10-undecenoic acid, 7-octadecanoic acid, 7- Hexadecenoic acid, 8,10-octadecenoic acid, 10,13-octadecadienoic acid and 9-dodecenoic acid.

More preferably, the saturated fatty acid is selected from the group consisting of docosanoic acid, eicosanoic acid, heneicosanoic acid, dodecanoic acid, heptadecanoic acid, hexadecanoic acid, octadecanoic acid, octanoic acid, pentadecanoic acid, Wherein the unsaturated fatty acids are selected from the group consisting of 11-eicosanoic acid, 11,13-eicosanoic acid, 13-docosanoic acid, 9,12,15-octadecatrienoic acid, 9,12-octadecadienoic acid, 9-hexadecenoic acid and 9-octadecenoic acid.

As used herein, the term " organic acid " refers collectively to organic compounds (e.g., amino acids) having acidic character, the term " polyacetylene " is an acetylenic hydrocarbon, polyunsaturated alcohol, and the term " terpenoid " Is an organic compound having a carbon number in multiples of 5.

According to another aspect of the present invention, the present invention provides a composition comprising 75-99 wt% vegetable omega 3, 0.001-10 wt% of Ginkgo biloba extract per total composition, and 0.001-15 wt% botanical vitamin Or a pharmaceutically acceptable salt thereof.

The food composition for obesity control of the present invention is based on the vegetable omega-3, ginkgo biloba extract and vegetable vitamin contained in the food composition for improving blood circulation or lipid composition of the present invention described above. The content common to both of them is excessive In order to avoid complexity, the description thereof is omitted.

According to a preferred embodiment of the present invention, the food composition for obesity control according to the present invention comprises 85-98% by weight of vegetable omega 3, 0.5-5% by weight of Ginkgo biloba extract of the whole composition and 0.5 - 10% by weight of vegetable vitamins; More preferably, the composition comprises 92-98% by weight vegetable omega 3, 0.5-3% by weight of the ginkgo leaf extract, based on the total composition, and 0.5-5% by weight vegetable vitamin with respect to the total composition; More preferably 95-98 wt.% Vegetable omega 3, 0.5-2 wt.% Ginkgo leaf extract for the total composition, and 0.5-3 wt.% Vegetable vitamin for the total composition.

According to a preferred embodiment of the present invention, the food composition for obesity control of the present invention may further comprise 0.05-3 parts by weight, more preferably 0.1-3 parts by weight, of the ginseng lipid-soluble component per 100 parts by weight of the composition More preferably from 0.1 to 2.5 parts by weight based on the total composition, even more preferably from 0.3 to 2 parts by weight based on the total composition.

 The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food and food additives. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art. For example, as a health food, an extract of ginseng can be prepared in the form of tea, juice and drink, and then it can be ingested, granulated, encapsulated and powdered, and powdered, capsules, soft capsules, tablets, Or may be prepared by ingestion in the form of a liquid type composition. The functional foods may include beverages (including alcoholic beverages), fruits and processed foods thereof (such as canned fruits, bottles, jam, maal malt, etc.), fish, meat and processed foods such as ham, sausage, ), Breads and noodles (eg udon noodles, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, sugar, dairy products such as butter, cheese, edible vegetable oil, margarine, vegetable protein, The ginseng extract of the present invention can be added to foods, frozen foods and various kinds of seasonings (e.g., miso, soy sauce, sauce, etc.).

In the food composition for improving circulation of the present invention, a mineral compound (Ca, Mg, Zn, etc.), phospholipid Is more preferable because it can reinforce the bioactive effect.

In addition to the above components, natural additives such as natural flavors such as plum, lemon flavor, pineapple flavor or herb flavor, natural fruit juice, natural pigments such as Chlorophyllin and Flovonoid in order to enhance the taste as a known additive, , Honey, sugar alcohol, sugar, citric acid, and sodium citrate.

The food composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, And carbonating agents used in carbonated drinks. In addition, the food composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The features and advantages of the present invention are summarized as follows:

(a) The present invention provides a food composition for improving blood circulation or improving blood lipid comprising vegetable omega-3, ginkgo leaf extract and vegetable vitamin at a specific weight ratio.

(b) The omega-3 contained in the composition of the present invention is vegetable omega-3 extracted from microalgae and is excellent in blood circulation improvement and cholesterol lowering effect.

(c) In addition, a composition further comprising a ginseng lipid-soluble component in a composition of vegetable omega-3, ginkgo leaf extract and vegetable vitamin is more excellent in cholesterol and neutral lipid lowering efficacy.

(d) When the composition of the present invention is ingested, the amount of triglyceride and LDL-cholesterol is decreased, thereby improving the blood circulation improving effect, and thus it can be utilized as a pharmaceutical composition or a health food composition for various blood circulation improvement.

FIG. 1 is a graph showing the results of PT analysis as an in vivo test using the composition of the present invention. 4: vegetable Omega 3 + Ginkgo biloba extract + vegetable vitamin group, 5: vegetable Omega 3 + ginseng lipid soluble ingredient + Ginkgo biloba extract + Vegetable vitamin administration group.
Fig. 2 is a graph showing the results of APTT analysis as an in vivo test using the composition of the present invention.
FIG. 3 is a graph showing the results of total cholesterol analysis as an in vivo test using the composition of the present invention.
FIG. 4 is a graph showing the result of neutral lipid analysis as an in vivo test using the composition of the present invention.
FIG. 5 is a graph showing the results of HDL analysis as an in vivo test using the composition of the present invention.
FIG. 6 is a graph showing the results of LDL analysis as an in vivo test using the composition of the present invention.
7 and 8 are graphs showing weight gain and weight gain tendency of the rats used in the in vivo test using the composition of the present invention, respectively. In group G3 (vegetable omega-3 treated group) and group G5 (vegetable omega 3 + Ginkgo biloba extract + vegetable vitamin treated group) decreased by 1.14%, group 6 (vegetable omega 3 + Extract + vegetable vitamin) decreased by 4.02% (y-axis unit: g).

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example

Example 1. Extraction of lipid-soluble components of ginseng

The 6-year-old ginseng purchased from the market was lightly washed with warm water, and then the ginseng body and roots were pulverized to extract a lipid-soluble component of ginseng using a carbon dioxide supercritical extraction method (supercritical fluid extraction apparatus: CO ₂ Supercritical Fluid Extraction Autoclave). The supercritical CO ₂ was used as the extraction solvent, and the total amount was recovered by reducing it to the gaseous state after use.

Two kinds of ginseng samples were used: body and root. In order to maximize the contact area with the solvent, liposoluble materials were extracted from the injection port of supercritical fluid extractor after grinding. The ginseng roots showed higher yields than the other conditions at a pressure of 350 bar and a temperature of 40 ℃ and a yield of 1.49% and 250 bar and a yield of 1.30% at 60 ℃. The ginseng body part exhibited a relatively high yield among various other conditions at a pressure of 250 bar at a temperature of 60 ° C and a yield of 0.86% and 350 bar and a yield of 0.80% at a temperature of 50 ° C. Four substances were selected as candidates for the ginseng roots and body extracts obtained by supercritical fluid extraction. Table 1 and Table 2 summarize the extraction yields of each sample and condition using the supercritical fluid extraction method described above. As a result, it was confirmed that the roots of ginseng showed relatively higher yield than that of the ginseng body, and the extraction yield of lipophilic components of the ginseng root and ginseng body was about 1%, establishing the basic conditions for mass production.

Extraction Yield by Supercritical Fluid Extraction Method by Specimen / Condition (Ginseng Root) number Temperature (℃) Pressure (bar) Time (min) Extraction yield (%) One 30 100 120 0.80 2 150 120 0.82 3 200 120 0.81 4 250 120 0.84 5 300 120 0.83 6 350 120 0.85 7 40 100 120 0.90 8 150 120 0.95 9 200 120 0.92 10 250 120 0.96 11 300 120 1.00 12 350 120 1.49 13 50 100 120 0.98 14 150 120 1.16 15 200 120 1.12 16 250 120 1.13 17 300 120 1.14 18 350 120 1.15 19 60 100 120 1.00 20 150 120 1.02 21 200 120 1.08 22 250 120 1.30 23 300 120 1.25 24 350 120 1.24

Extraction Yield by Samples / Conditions by Supercritical Fluid Extraction Method (Ginseng Body) number Temperature (℃) Pressure (bar) Time (min) Extraction yield (%) 25 30 100 120 0.50 26 150 120 0.57 27 200 120 0.54 28 250 120 0.55 29 300 120 0.56 30 350 120 0.52 31 40 100 120 0.60 32 150 120 0.62 33 200 120 0.66 34 250 120 0.73 35 300 120 0.73 36 350 120 0.77 37 50 100 120 0.70 38 150 120 0.73 39 200 120 0.75 40 250 120 0.79 41 300 120 0.79 42 350 120 0.80 43 60 100 120 0.71 44 150 120 0.73 45 200 120 0.75 46 250 120 0.86 47 300 120 0.78 48 350 120 0.65

Example  2: Supercritical  Analysis of Ginseng Extracts Using Carbon Dioxide

The ginseng roots obtained in Example 1 and the ginseng root extracts obtained in the body were analyzed. The results are shown in Tables 3 and 4 below. The extraction conditions in Table 3 are 100-350 bar, 30-60 ° C, and the extraction conditions in Table 4 are 100-350 bar, 30-60 ° C.

A total of 30 components were detected in the roots of ginseng, 36 components were detected in the ginseng body, and more components were detected in the ginseng body than the ginseng roots in Example 1.

Analysis of Ginseng Root Extract Using Supercritical Carbon Dioxide number fatty acid One 2 3 4 5 6 7 8 9 One 11-eicosanoic acid o o o o o o o 2 11,13-Eiko Sadieno o o o o o o 3 13-docosanoic acid o o o o o o o 4 9,12,15-octadecatrienoic acid o o o o o o o o 5 9,12-octadecadienoic acid o o o o o o o o 6 9-hexadecenoic acid o o o o o o o 7 9-octadecenoic acid o o o o o o o 8 Tokosano Mountain o o o o o o o 9 Eikosano o o o o o o o 10 Haneikosano o o o o 11 Dodecanoic acid o o o 12 Heptadecanoic acid o o o o o o o o 13 Hexadecanoic acid o o o o o o o o 14 Octadecanoic acid o o o o o o o o 15 Octanoic acid o o o o o o 16 Pentadecanoic acid o o o o o o o o 17 Tetradecanoic acid o o o o o o o 18 Tricosanoic acid o o o o o 19 Nonadecano o o o 20 11-octadecenoic acid o 21 Hexanoic acid o 22 8,11-octadecadienoic acid o 23 7,10-hexadecadienoic acid o o 24 Decanoic acid o o o 25 13-octadecenoic acid o 26 6,9,12-octadecatrienoic acid 27 9,15-octadecadienoic acid o 28 Eicosanoic acid o 29 Propanoic acid o 30 10-undecenoic acid 31 2-pyridinepropanoic acid 32 7-hexadecenoic acid 33 Undecano 34 8,10-octadecenoic acid 35 11,14-eicosanoic acid 36 Octadecadiynoic acid (10,13-octadecadienoic acid) 37 3-nonenoic acid 38 9-dodecenoic acid 39 Suishi Nanshan 40 Cyclopropylmethylphosphinic acid o o 41 Cyclopropanecotanoic acid o o o o

Analysis of Ginseng Body Extract Using Supercritical Carbon Dioxide number fatty acid 10 11 12 13 14 15 16 17 18 One 11-eicosanoic acid o o o o o o o o 2 11,13-Eiko Sadieno o o o o o o 3 13-docosanoic acid o o o o o o o 4 9,12,15-octadecatrienoic acid o o o o o o o o o 5 9,12-octadecadienoic acid o o o o o o 6 9-hexadecenoic acid o o o o o o o o o 7 9-octadecenoic acid o o o o o o o o 8 Tokosano Mountain o o o o o o o o 9 Eikosano o o o o o o o o 10 Haneikosano o o o o 11 Dodecanoic acid o o o o o 12 Heptadecanoic acid o o o o o 13 Hexadecanoic acid o o o o o 14 Octadecanoic acid o o o o o o o o o 15 Octanoic acid o o o o o o o o o 16 Pentadecanoic acid o o o o o o o 17 Tetradecanoic acid o o o o o o o 18 Tricosanoic acid o o o o o o 19 Nonadecano o o 20 11-octadecenoic acid o 21 Hexanoic acid 22 8,11-octadecadienoic acid o o 23 7,10-hexadecadienoic acid o o 24 Decanoic acid 25 13-octadecenoic acid o 26 6,9,12-octadecatrienoic acid o 27 9,15-octadecadienoic acid 28 Eicosanoic acid 29 Propanoic acid o o 30 10-undecenoic acid o 31 2-pyridinepropanoic acid o 32 7-hexadecenoic acid o 33 Undecano o o 34 8,10-octadecenoic acid o 35 11,14-eicosanoic acid o 36 Octadecadiynoic acid (10,13-octadecadienoic acid) o o o o 37 3-nonenoic acid o 38 9-dodecenoic acid o 39 Suishi Nanshan o 40 Cyclopropylmethylphosphinic acid 41 Cyclopropanecotanoic acid o o o o o o

Example  3. Assessment of blood circulation improvement effect by oral administration

After 6 weeks old rats (Sprague Dawyer, Orient Bio) were fed for 1 week, they were fed a diet of high fat diet (HFD 45%), omega 3, ginkgo leaf extract, ginseng roots And 45% dietary HFD group supplemented with vegetable vitamins. The plant omega-3 was extracted from the microalgae, Schizochytrium sp. The plant vitamins used were niacin, pantothenic acid, vitamin B6 hydrochloride, vitamin B2, vitamin B1 hydrochloride, folic acid and biotin.

General Diet and HFD 45% Dietary Composition Table Furtherance AIN-76A HFD 45% cal gm% kcal% gm% kcal% protein 20 21 24 20 carbohydrate 66 68 41 35 Fat 5 12 24 45 kcal / kg 3,902 - 4,776 - ingredient g kcal g kcal Casein (milk) 200 800 200 800 Corn starch 150 600 155.036 620 Sucrose 500 2,000 50 200 Dextrose 0 0 132 528 cellulose 50 0 50 0 Soybean oil 0 0 25 225 Lard 0 0 175 1,575 Mineral mixture 35 0 35 0 Vitamin mixture 10 40 10 40 Tertiary butyl hydroquinone (TBHQ) 0 0 0.014 0 L-cysteine 0 0 3 12 Tartaric acid choline 2 0 2.5 0 Sum 1,000 3,902 837.6 4,000

The design of the experimental group is as follows:

Test group Diet Dosing substance Dose (mg / kg) G1 A normal diet - 0 G2 HFD 45% - 0 G3 HFD 45% Vegetable omega 3 210 G4 HFD 45% Vegetable Omega 3 + Ginkgo biloba extract + Vegetable Vitamin 210 + 2 + 4 G5 HFD 45% Vegetable Omega-3 + Ginseng Oil-soluble component + Ginkgo biloba extract + Vegetable vitamin 210 + 1 + 2 + 4

The rats were fed with the dietary composition of Table 5 and the composition of Table 6 was orally administered once / day for 6 weeks. The first day of administration was defined as day 0. The dose was calculated as 210 mg / kg based on the most recently measured body weight before administration. On the 63rd day after administration, rats were anesthetized with ether, and whole blood was collected from the jugular vein. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured in each blood sample. As a result, PT ratios were increased in all groups compared to Group 2 (control group), which received only 45% HFD in SD rats (Table 7 and Fig. 1). That is, 54.4% of the G3 group, 52.3% of the G4 group, and 53.1% of the G5 group were delayed compared to G2 (control group). This means that the composition of vegetable omega 3, ginseng lipid soluble component, ginkgo leaf extract and vegetable vitamin affect the external factor of blood coagulation.

Measurement results of PT and APTT group G1 G2 G3 G4 G5 PT (sec) 22.90 16.66 25.72 25.38 25.50 APTT (sec) 19.45 16.33 18.00 19.01 20.02 Number of mice 7 7 7 7 7

On the other hand, a slight coagulation time was delayed in all groups compared to group 2 (control group) which received only 45% of HFD, but no significant change was observed (Table 7 and FIG. 2). That is, the blood clotting time was delayed by 10.2% for the G3 group, 16.4% for the G4 group, and 22.5% for the G5 group compared to G2 (control group). This means that the composition of vegetable omega-3, ginseng lipid-soluble component, ginkgo leaf extract and vegetable vitamin slightly affects the intracellular factor of blood coagulation.

In the above results, it is predicted that the difference between the normal group (Group 1) and the other administration group (Group 3 to Group 5) is the effect of HFD 45%, but the omega 3, ginseng oil, ginkgo leaf extract and vegetable vitamin There seems to be some room.

Example  4. Neutral lipid and cholesterol analysis

An in vivo test was performed to measure total cholesterol (Tc), triglyceride (TG), HDL-cholesterol and LDL-cholesterol levels in the same experimental design as in Example 3 above.

Results of total cholesterol, triglyceride, HDL, LDL analysis by oral administration (unit: (mg / dl) group G1 G2 G3 G4 G5 Tc 59.50 88.83 75.63 73.75 71.63 TG 122.67 355.80 232.50 222.13 168.13 HDL 30.00 34.00 38.29 39.75 40.83 LDL 8.67 9.88 8.25 7.25 7.01

As can be seen in Table 8 and FIG. 3, the total cholesterol level was lower in all experimental groups (G3-G5) than in the control group (group G2). In particular, the group G3 (vegetable omega-3-treated group) and the group G4 (vegetable omega-3 + ginkgo leaf extract + vegetable vitamin-treated group) received 17.0% Vitamins) showed about 20% total cholesterol reduction effect.

On the other hand, as can be seen from Table 8 and FIG. 4, it was found that the total cholesterol level was lower in all the administration groups than the control group (group G2). In particular, compared with the control group, 34.7% of the group G3 (plant-derived omega 3-treated group), group G4 (planted omega 3 + Ginkgo biloba extract + vegetable vitamin-treated group) received 37.8%, group G5 (vegetable omega 3 + Vegetable vitamins) showed about 53% reduction of neutral quality. In addition, the group G5 of the above group showed the most remarkable neutral lipid-lowering effect.

When compared to group G4 (plant Omega 3 + Ginkgo biloba extract + vegetable vitamin group) and group G5 (vegetable Omega 3 + ginseng lipid soluble component + Ginkgo biloba extract + vegetable vitamin group), TG levels in both groups were higher And the synergistic effect of vegetable Omega 3, Ginkgo biloba extract and ginseng lipid soluble ingredient was found to be large, considering that the group containing the patented ginseng lipid soluble ingredient had a large effect of reducing the neutral lipid.

In Table 8 and FIG. 5, the HDL-cholesterol level was 12.6% in the group G3 (vegetable omega 3-treated group), 16.9% in the group G4 (plant omega 3 + ginkgo leaf extract + vegetable vitamin-treated group) Group G5 (vegetable omega 3 + lipid soluble component of ginseng + Ginkgo biloba extract + vegetable vitamin) showed 20.1% increase of HDL.

As can be seen in Table 8 and FIG. 6, LDL levels were lower in all groups than in the control group (group 2), and LDL-cholesterol levels in comparison with the control group were lower in group G3 (vegetable omega 3 group) (Glycosylation of Ginseng) + Ginkgo biloba extract + Vegetable Vitamin) showed about 29.0% reduction of LDL in group G5 (16.5%), Group G4 (Plant Omega 3 + Ginkgo biloba extract + .

As shown in FIG. 7, the weight gain was lower in all groups than in the control group (group 2), and the weight gain in comparison with the control group was 0.22% in the group G3 (vegetable omega 3 group) Group G4 (vegetable omega 3 + Ginkgo biloba extract + vegetable vitamin group) and group G5 (vegetable omega 3 + ginseng lipid soluble extract + ginkgo leaf extract + vegetable vitamin) showed a decrease in weight gain by about 4.02%.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (12)

A vegetable omega-3 derived from microalgae in an amount of 75-99% by weight, a ginkgo leaf extract in an amount of 0.001-10% by weight based on the whole composition, a vegetable vitamin in an amount of 0.001-15% by weight with respect to the whole composition, A food composition for improving cholesterol and triglyceride comprising 0.05-3 parts by weight of a ginseng fat-soluble component per 100 parts by weight of a mixed composition of omega-3, ginkgo leaf extract and vegetable vitamin.
delete 2. The composition of claim 1, wherein the microalgae is Spirulina, Chlorella or Schizochytrium genus.
The food composition of claim 1, wherein the composition further comprises a blood circulation improving adjuvant.
The composition according to claim 4, wherein the blood circulation improving agent is omega-6 fatty acid, omega-7 fatty acid, omega-9 fatty acid or lecithin.
The composition of claim 1, wherein the composition comprises 85-98% by weight of vegetable omega 3, 0.05-3% by weight of the total composition of Ginkgo biloba extract, and 0.05-5% by weight of vegetable vitamin ≪ / RTI > delete delete delete delete delete delete

Images